X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with WYETH LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs WYETH LTD - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA WYETH LTD GLENMARK PHARMA/
WYETH LTD
 
P/E (TTM) x 11.9 27.7 43.0% View Chart
P/BV x 3.2 5.3 58.9% View Chart
Dividend Yield % 0.4 1.3 30.1%  

Financials

 GLENMARK PHARMA   WYETH LTD
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
WYETH LTD
Mar-13
GLENMARK PHARMA/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs9931,044 95.1%   
Low Rs729818 89.2%   
Sales per share (Unadj.) Rs325.5298.6 109.0%  
Earnings per share (Unadj.) Rs39.357.2 68.6%  
Cash flow per share (Unadj.) Rs48.758.4 83.3%  
Dividends per share (Unadj.) Rs2.0017.00 11.8%  
Dividend yield (eoy) %0.21.8 12.7%  
Book value per share (Unadj.) Rs159.2249.5 63.8%  
Shares outstanding (eoy) m282.1722.72 1,241.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.63.1 84.8%   
Avg P/E ratio x21.916.3 134.7%  
P/CF ratio (eoy) x17.715.9 111.0%  
Price / Book Value ratio x5.43.7 144.9%  
Dividend payout %5.129.7 17.1%   
Avg Mkt Cap Rs m242,99121,157 1,148.5%   
No. of employees `00013.00.5 2,635.6%   
Total wages/salary Rs m16,408400 4,102.0%   
Avg. sales/employee Rs Th7,083.913,787.4 51.4%   
Avg. wages/employee Rs Th1,265.4813.0 155.6%   
Avg. net profit/employee Rs Th855.12,643.3 32.3%   
INCOME DATA
Net Sales Rs m91,8576,783 1,354.1%  
Other income Rs m374353 106.0%   
Total revenues Rs m92,2307,136 1,292.5%   
Gross profit Rs m20,3671,617 1,259.3%  
Depreciation Rs m2,64427 9,938.7%   
Interest Rs m2,3736 43,149.1%   
Profit before tax Rs m15,7241,938 811.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-810-5 15,872.5%   
Tax Rs m3,827632 605.3%   
Profit after tax Rs m11,0881,301 852.6%  
Gross profit margin %22.223.8 93.0%  
Effective tax rate %24.332.6 74.6%   
Net profit margin %12.119.2 63.0%  
BALANCE SHEET DATA
Current assets Rs m68,7466,984 984.4%   
Current liabilities Rs m27,0272,056 1,314.6%   
Net working cap to sales %45.472.6 62.5%  
Current ratio x2.53.4 74.9%  
Inventory Days Days8599 85.6%  
Debtors Days Days9624 399.1%  
Net fixed assets Rs m24,132244 9,878.2%   
Share capital Rs m282227 124.2%   
"Free" reserves Rs m44,6435,441 820.5%   
Net worth Rs m44,9255,668 792.6%   
Long term debt Rs m45,36325 181,453.6%   
Total assets Rs m117,6397,901 1,488.9%  
Interest coverage x7.6353.3 2.2%   
Debt to equity ratio x1.00 22,893.1%  
Sales to assets ratio x0.80.9 90.9%   
Return on assets %11.416.5 69.2%  
Return on equity %24.722.9 107.6%  
Return on capital %19.134.0 56.2%  
Exports to sales %00.2 0.0%   
Imports to sales %036.3 0.0%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs mNA2,465 0.0%   
Fx inflow Rs m56,15215 369,418.4%   
Fx outflow Rs m8,0842,677 302.0%   
Net fx Rs m48,068-2,662 -1,805.7%   
CASH FLOW
From Operations Rs m6,574923 712.1%  
From Investments Rs m-7,124317 -2,247.9%  
From Financial Activity Rs m5,432-481 -1,129.2%  
Net Cashflow Rs m1,992759 262.5%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 6.9 11.3 61.1%  
FIIs % 34.4 7.2 477.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 30.4 34.5%  
Shareholders   56,727 21,978 258.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  NOVARTIS  DR. DATSONS LABS  

Compare GLENMARK PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Feb 16, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS